Day: February 24, 2025

CAMBRIDGE, Mass., Feb. 24, 2025 (GLOBE NEWSWIRE) — Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that management will participate in fireside chats at the following upcoming investor conferences:TD Cowen 45th Annual Health Care Conference on Monday, March 3, 2025, at 1:50 p.m. ET Leerink Partners Global Biopharma Conference on Monday, March 10, 2025, at 1:40 p.m. ET Barclays Global Healthcare Conference on Tuesday, March 11, 2025, at 3:30 p.m. ETThe live webcasts will be available in the investor section of the company’s website at www.beamtx.com and will be archived for 60 days following the presentation. About Beam TherapeuticsBeam Therapeutics (Nasdaq: BEAM) is a biotechnology company committed to establishing the leading,...

NEW YORK, Feb. 24, 2025 (GLOBE NEWSWIRE) — OTC Markets Group Inc. (OTCQX: OTCM), operator of regulated markets for trading 12,000 U.S. and international securities, today announced ZRCN Inc. (OTCQX: ZRCN), is a manufacturer and seller of digitally-enabled hand-tools, has qualified to trade on the OTCQX® Best Market. ZRCN, Inc. begins trading today on OTCQX under the symbol “ZRCN.” U.S. investors can find current financial disclosure and Real-Time Level 2 quotes for the company on www.otcmarkets.com. Trading on the OTCQX Market offers companies efficient, cost-effective access to the U.S. capital markets. Streamlined market requirements for OTCQX are designed to help companies lower the cost and complexity of being publicly traded, while providing transparent trading for their investors. To qualify for OTCQX, companies must meet...

Amendment provides financial flexibility to the Company by deferring all interest as well as principal redemption payments through September 2025, while reducing near-term cash needs NEW YORK, Feb. 24, 2025 (GLOBE NEWSWIRE) — Eyenovia, Inc. (NASDAQ: EYEN) (“Eyenovia” or the “Company”), an ophthalmic technology company focused on completing development of its proprietary Optejet® device, today announced that it has entered into an amendment to its outstanding senior secured convertible debt due November 1, 2025 (the “Amendment”).The Amendment defers the Company’s monthly interest and amortization payments from March 2025 through September 2025. Additionally, the Amendment allows the full conversion of the debt into common shares of the Company commencing on April 1, 2025, at a price of $1.68 per share. “This Amendment strengthens...

BOSTON, Feb. 24, 2025 (GLOBE NEWSWIRE) — Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (Atea or Company), a clinical-stage biopharmaceutical company engaged in the discovery and development of oral antiviral therapeutics for serious viral diseases, today announced the appointment of Arthur S. Kirsch to the Company’s Board of Directors, effective immediately. Mr. Kirsch has decades of experience in investment banking and capital markets, as well as extensive knowledge of the healthcare and life sciences industries. Mr. Kirsch is currently a Senior Advisor with Alvarez & Marsal’s Life Sciences Industry Group, and over the course of his 30-year career has held numerous roles in mergers and acquisitions and equity capital markets at global investment banks. Over that time, he executed a wide range of strategic advisory assignments...

Study comparing BioStem’s proprietary amnion chorion allograft versus the standard of care aims to demonstrate superior outcomes, further validating its clinical efficacy to support market expansion POMPANO BEACH, Fla., Feb. 24, 2025 (GLOBE NEWSWIRE) — BioStem Technologies, Inc. (OTC: BSEM), a leading MedTech company focused on the development, manufacturing, and commercialization of placental-derived products for advanced wound care, announces Institutional Review Board (IRB) approval for a clinical study to evaluate its proprietary BioREtain® Amnion Chorion (BR-AC) for the treatment of venous leg ulcers (VLU). This study aims to assess the efficacy of BR-AC compared to standard of care in patients with non-healing VLUs, providing critical data to support continued market adoption of its proprietary technology. Jason Matuszewski,...

NEW YORK, Feb. 24, 2025 (GLOBE NEWSWIRE) — Veri Medtech Holdings (OTC Markets: (“VRHI”) (“Veri Medtech”) announced today that it has reached 1.3 million patient registrations. “2025 will prove to be a transformative year, as we work to strategically position Veri Medtech (VRHI) to be an alternative to current telemedicine providers.  With thousands of new patient registrations per month, via our proprietary healthcare technology platform, Veri Medtech (VRHI) is poised and positioned to continue to capture marketshare as a leading provider for health and wellness prescription and non-prescription products and services, in the estimated $114 billion market for telemedicine, for years to come,” said Sam Adetunji, CEO, Veri Medtech Holdings. About Veri Medtech (OTC Markets: VRHI): Veri Medtech is a leading provider of health...

LONGUEUIL, Quebec, Feb. 24, 2025 (GLOBE NEWSWIRE) — Azimut Exploration Inc. (“Azimut” or the “Company”) (TSXV:AZM) (OTCQX:AZMTF) is pleased to announce the voting results for its Annual General Meeting (the “Meeting”) of shareholders held February 20, 2025. A total of 45,175,458 shares were represented in person or by proxy at the Meeting corresponding to 52.72% of the issued and outstanding shares of the Company. Shareholders approved all matters presented at the meeting as follows:  Votes For % For Vote Withheld % Withheld Total VotedElections of Directors          Glenn J. Mullan 43,224,896 99.35 % 284,438 0.65 % 43,509,334Jean-Marc Lulin 43,393,048 99.73 % 116,286 0.27 % 43,509,334Jean-Charles Potvin 43,363,648 99.67 % 145,686 0.33 % 43,509,334Jacques Simoneau 43,386,548 99.72 % 122,786 0.28 % 43,509,334Michel...

MURRAY, Utah, Feb. 24, 2025 (GLOBE NEWSWIRE) — Beyond, Inc. (NYSE:BYON), owner of Bed Bath & Beyond and Overstock, announced today it has completed the previously announced transaction pursuant to the Company’s Asset Purchase Agreement with BBBY Acquisition Co. LLC (“BBBY”) to acquire the global rights of the Buy Buy Baby brand. The purchase price of $5 million includes certain assets, databases, domains, intellectual property, vendor relationships and content related to Buy Buy Baby. Marcus Lemonis, Executive Chairman of Beyond, commented, “As part of our strategy to expand our market reach, I am excited to announce we completed the acquisition of the Buy Buy Baby brand ahead of schedule. We believe bringing these two iconic brands, Bed Bath & Beyond and Buy Buy Baby, back together significantly strengthens our customer...